{"preliminary_commentary":{"by_channel":{"x_thread":16,"youtube":10,"podcast":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04538742\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["trastuzumab deruxtecan"],["trastuzumab deruxtecan","durvalumab"],["trastuzumab deruxtecan","pertuzumab"]],"indication":"HER2-positive metastatic breast cancer","name":"DESTINY-Breast07","nct_id":"NCT04538742","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-breast07-nct04538742. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DB-07","arms":[{"description":"T-DXd and Durvalumab","label":"Module 1- T-DXd and Durvalumab","type":"EXPERIMENTAL"},{"description":"T-DXd and Pertuzumab","label":"Module 2- T-DXd and Pertuzumab","type":"EXPERIMENTAL"},{"description":"T-DXd and Paclitaxel (Arm not initiated in Part 2)","label":"Module 3- T-DXd and Paclitaxel","type":"EXPERIMENTAL"},{"description":"T-DXd and Durvalumab and Paclitaxel (Arm not initiated in Part 1 and Part 2)","label":"Module 4- T-DXd and Durvalumab and Paclitaxel","type":"EXPERIMENTAL"},{"description":"T-DXd","label":"Module 0- T-DXd","type":"EXPERIMENTAL"},{"description":"T-DXd and tucatinib (Arm not initiated in Part 2)","label":"Module 5 - T-DXd and Tucatanib","type":"EXPERIMENTAL"},{"description":"T-DXd and tucatinib in patients with active brain metastases (Part 2 Only) (Arm not initiated)","label":"Module 6 - T-DXd and Tucatinib","type":"EXPERIMENTAL"},{"description":"T-DXd monotherapy in patients with active brain metastases (Part 2 Only)","label":"Module 7 - T-DXd","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo Company, Limited"],"completion_date":{"date":"2030-01-31","type":"ESTIMATED"},"conditions":["Metastatic Breast Cancer"],"enrollment":{"count":245,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Trastuzumab deruxtecan","otherNames":["DS-8201a, T-DXd"],"type":"DRUG"},{"name":"Durvalumab","otherNames":["MEDI4736"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Pertuzumab","otherNames":[],"type":"DRUG"},{"name":"Tucatinib","otherNames":["ONT-380"],"type":"DRUG"}],"last_update":"2025-12-08","lead_sponsor":"AstraZeneca","official_title":"A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2025-01-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Occurrence of adverse events (AEs)- Part 1","timeFrame":"Up to follow-up period, approximately 53 months"},{"measure":"Occurrence of serious adverse events (SAEs)- Part 1","timeFrame":"Up to follow-up period, approximately 53 months"},{"measure":"Occurrence of adverse events (AEs)- Part 2","timeFrame":"Up to follow-up period, approximately 53 months"},{"measure":"Occurrence of serious adverse events (SAEs)- Part 2","timeFrame":"Up to follow-up period, approximately 53 months"}],"references":[],"start_date":{"date":"2020-12-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04538742"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-breast07-nct04538742"}